Early local activation of complement in aqueous humour of patients with age-related macular degeneration
Early local activation of complement in aqueous humour of patients with age-related macular degeneration
复制标题
DOI：
10.1038/s41433-019-0501-4
复制
发表时间：
2019-12-01
期刊：
影响因子：
3.9
通讯作者：
Fauser, S.
中科院分区：
文献类型：
--
作者：
Altay, L.;Sitnilska, V.;Fauser, S.
目的探讨早期、中期和新生血管性年龄相关性黄斑变性(AMD)患者房水中的补体激活情况。 患者和方法前瞻性收集79例AMD患者(早期、中期和新生血管性)和77例年龄匹配的对照者的房水。测量补体蛋白 3 (C3)、激活产物补体因子 3a (C3a) 和 Ba、C3b/iC3b、补体因子 B、H 和 I（CFB、CFH 和 CFI）的水平以及总蛋白浓度。使用协变量分析对数据进行建模，以评估患者年龄和青光眼状态以及样本总蛋白浓度对各组补体蛋白浓度的影响。结果早期 (p = 0.016)、中期 (p = 0.003) 和新生血管 (p = 0.018) AMD 患者房水中 C3a 浓度显着增加，而仅早期 AMD 患者中 C3 浓度显着增加 (p = 0.019)。新生血管性 AMD 患者房水中 CFB 和 CFH 水平显着升高（分别为 p = 0.023 和 p = 0.018）。 结论 我们的研究结果为 AMD 患者早期局部补体失调提供了证据，表明补体途径抑制可能是 AMD 早期的临床相关干预措施。
Objective To investigate complement activation in aqueous humour of patients with early, intermediate and neovascular age-related macular degeneration (AMD).Patients and methods Aqueous humour of 79 AMD patients (early, intermediate and neovascular) and 77 age-matched controls was prospectively collected. The levels of the complement protein 3 (C3), activation products complement factor 3a (C3a) and Ba, C3b/iC3b, complement factors B, H and I (CFB, CFH and CFI), and total protein concentration were measured. Data were modelled using covariate analysis to assess the impact of age and glaucoma status of patients and total protein concentration of samples on complement protein concentration across groups.Results C3a concentration was significantly increased in the aqueous humour of early (p = 0.016), intermediate (p = 0.003) and neovascular (p = 0.018) AMD patients, whilst C3 concentration was significantly increased in early AMD patients only (p = 0.019). Levels of CFB and CFH were significantly increased in the aqueous humour of neovascular AMD patients (p = 0.023 and p = 0.018, respectively).Conclusions Our findings provide evidence for early local complement dysregulation in AMD patients, suggesting that complement pathway inhibition may be a clinically relevant intervention for early stages of AMD.